HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

The incidence of lymph node metastasis in patients with different oncogenic driver mutations among T1 non-small-cell lung cancer.

AbstractOBJECTIVE:
To investigate the incidence and distribution of lymph node metastasis in patients with different gene mutations among pathological T1 non-small-cell lung cancers (NSCLC).
METHODS:
NSCLC cases resected in our institution between 2016 and 2018 were included. Driver mutation testing was performed in all resected tumor tissues. These patients were grouped by the type of gene mutations. On the basis of protein that mutant-genes encoded involved in the molecular pathway, the genotypes were further classified into four distinct groups: upstream receptor mutant protein (EGFR, HER2 and MET); downstream regulator mutant protein (KRAS and BRAF); fusion mutant protein (ROS1, ALK and RET) and the wild type group. The incidence of lymph node metastasis was compared among different groups.
RESULTS:
Of the 1052 patients enrolled, the frequency of positive mutations was 68.0%. The incidence of lymph node metastasis were as follows: wild type (19.3%), ROS1 (72.8%), BRAF (55.5%), ALK (44.7%), HER2 (40%), RET (23.1%), KRAS (15.3%), EGFR (15.3%) and MET mutation (0%) (P < 0.001). The incidence of lymph node metastasis was significantly higher in fusion mutant protein group (45.1%) compared with others (wild type 19.3%, downstream regulator mutant protein 19.1%, upstream receptor mutant protein 15.3%, all P < 0.001). Patients with fusion genes also showed higher proportion of vascular invasion and positive lymph node ratio of greater than 0.33 compared to others.
CONCLUSION:
Different genotypes of NSCLC have different propensity to develop lymph node metastasis. Cases of fusion gene mutations had a higher risk and burden of lymph node metastasis than other genotypes, which may indicate that more intensive treatment or surveillance strategies should be applied for these patients.
AuthorsZhichao Liu, Hengrui Liang, Jie Lin, Xiuyu Cai, Zhenkui Pan, Jun Liu, Xiaohong Xie, Caichen Li, Bo Cheng, Yi Zhao, Jianxing He, Wenhua Liang
JournalLung cancer (Amsterdam, Netherlands) (Lung Cancer) Vol. 134 Pg. 218-224 (08 2019) ISSN: 1872-8332 [Electronic] Ireland
PMID31319984 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2019 Elsevier B.V. All rights reserved.
Chemical References
  • Biomarkers, Tumor
Topics
  • Adult
  • Aged
  • Alleles
  • Biomarkers, Tumor
  • Carcinoma, Non-Small-Cell Lung (epidemiology, genetics, pathology)
  • Female
  • Genotype
  • Humans
  • Incidence
  • Lung Neoplasms (epidemiology, genetics, pathology)
  • Lymph Nodes (pathology)
  • Lymphatic Metastasis
  • Male
  • Middle Aged
  • Mutation
  • Neoplasm Staging
  • Oncogenes

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: